Chromocell Therapeutics Corporation (CHRO)
NYSEAMERICAN: CHRO · Real-Time Price · USD
0.631
+0.012 (1.97%)
At close: Nov 21, 2024, 4:00 PM
0.589
-0.042 (-6.72%)
After-hours: Nov 21, 2024, 7:55 PM EST
Chromocell Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Cash & Equivalents | 1.25 | 0.1 | 0.06 | - | - |
| Cash & Short-Term Investments | 1.25 | 0.1 | 0.06 | - | - |
| Cash Growth | 5407.34% | 75.02% | - | - | - |
| Other Current Assets | 0.79 | - | - | - | 0.07 |
| Total Current Assets | 2.14 | 0.1 | 0.06 | - | 0.07 |
| Accounts Payable | 1.28 | 4.62 | 2.99 | 2.58 | 3.41 |
| Accrued Expenses | 0 | 0.65 | 0.22 | - | - |
| Short-Term Debt | 2.29 | 1.27 | 0.54 | - | 0.24 |
| Other Current Liabilities | - | 0.01 | 0.01 | - | - |
| Total Current Liabilities | 3.57 | 6.54 | 3.76 | 2.58 | 3.65 |
| Long-Term Debt | - | - | - | 1.1 | - |
| Common Stock | 0 | 0 | 0 | - | -3.58 |
| Additional Paid-In Capital | 18.12 | 7.07 | 2.43 | - | - |
| Retained Earnings | -19.55 | -13.52 | -6.14 | -3.68 | - |
| Total Common Equity | -1.43 | -6.44 | -3.71 | -3.68 | -3.58 |
| Total Liabilities & Equity | 2.14 | 0.1 | 0.06 | - | 0.07 |
| Total Debt | 2.29 | 1.27 | 0.54 | 1.1 | 0.24 |
| Net Cash (Debt) | -1.03 | -1.17 | -0.49 | -1.1 | -0.24 |
| Net Cash Per Share | -0.23 | -0.92 | -1.11 | - | - |
| Filing Date Shares Outstanding | 6.03 | 5.88 | 1.11 | - | - |
| Total Common Shares Outstanding | 5.82 | 3.91 | 1.11 | - | - |
| Working Capital | -1.43 | -6.44 | -3.71 | -2.58 | -3.58 |
| Book Value Per Share | -0.25 | -1.65 | -3.34 | - | - |
| Tangible Book Value | -1.43 | -6.44 | -3.71 | -3.68 | -3.58 |
| Tangible Book Value Per Share | -0.25 | -1.65 | -3.34 | - | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.